Can a contraceptive implant (etonogestrel) cause dyspnea or fatigue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Contraceptive Implants Cause Dyspnea or Fatigue?

Dyspnea and fatigue are not recognized side effects of etonogestrel contraceptive implants based on major clinical guidelines and FDA labeling, though one retracted study reported a single case of dyspnea leading to discontinuation.

Evidence from Guidelines and Drug Labels

The major contraceptive guidelines from the CDC 1, American Academy of Pediatrics 2, and other authoritative sources consistently identify bleeding irregularities (amenorrhea, spotting, prolonged bleeding) as the primary side effect and most common reason for implant discontinuation 2, 1. Neither dyspnea nor fatigue appear in the standard counseling recommendations for common side effects.

The FDA drug label for etonogestrel 3 does not list dyspnea or fatigue as adverse effects in its clinical trial data or warnings sections. The label focuses on cardiovascular risks (VTE), bleeding patterns, and insertion/removal complications.

Limited Research Evidence

Only one study mentions dyspnea in relation to etonogestrel implants:

  • A 1999 pilot study in Indonesia (n=200) reported one case of dyspnea that led to discontinuation over 4 years 4. However, this study has been retracted, significantly undermining its credibility.

  • A 2022 case series described dyspnea in patients with implant migration into the pulmonary artery 5—an extremely rare complication unrelated to the hormonal effects of the device itself.

  • A 2026 quality of life study found no impact on sexual function but noted decreased psychological, social, and environmental quality of life scores 6. This study did not specifically assess dyspnea or fatigue as outcomes.

Clinical Interpretation

If a patient using an etonogestrel implant presents with dyspnea or fatigue, these symptoms should not be attributed to the contraceptive implant without thorough evaluation for other causes. Consider:

  • Anemia from irregular bleeding: The implant commonly causes unpredictable bleeding patterns 1. Chronic blood loss could lead to iron-deficiency anemia, which manifests as fatigue and exertional dyspnea. Check hemoglobin/hematocrit and iron studies.

  • Cardiovascular events: While the implant itself has minimal cardiovascular risk compared to combined hormonal contraceptives 3, evaluate for VTE, especially if the patient has additional risk factors.

  • Device migration: Extremely rare, but pulmonary artery migration can cause cardiopulmonary symptoms 5. Consider if there's evidence the implant is not palpable in the arm.

  • Unrelated medical conditions: Thyroid disorders, cardiac disease, pulmonary conditions, depression, and many other causes of dyspnea/fatigue should be investigated.

Common Pitfalls

  • Do not dismiss these symptoms as implant-related without proper workup
  • Do not remove the implant as first-line management without identifying an actual cause
  • Do evaluate for anemia secondary to implant-related bleeding, which is a plausible indirect mechanism

The contraceptive implant should remain in place while investigating other causes of dyspnea and fatigue, unless a specific contraindication to continued use is identified.

Related Questions

What is the recommended workup for an 83-year-old woman with a long-standing history of exertional dyspnea?
What are the contraindications for Nexplanon (etonogestrel implant)?
Why do I have bleeding episodes twice a month while using the Nexplanon (etonogestrel) implant?
How should I evaluate and manage abnormal bleeding in a Nexplanon (etonogestrel implant) user?
What is the recommended workup for an elderly female patient with exertional dyspnea (shortness of breath upon exertion)?
What is the standard radical bladder‑preserving radiochemotherapy schedule for muscle‑invasive bladder cancer, including radiation dose, fractionation, and concurrent chemotherapy regimen?
Should I continue hemodialysis in a patient with intradialytic blood pressure of 210/100 mm Hg after three sublingual doses of clonidine 75 µg?
In a 27-year-old woman with recurrent urinary-type symptoms, negative urine cultures, and a molecular vaginal microbiome showing marked aerobic/enteric dysbiosis (high Escherichia coli, Enterococcus faecalis, Proteus mirabilis, Peptostreptococcus), profound Lactobacillus depletion, Candida parapsilosis, and Ureaplasma species, is a staged treatment plan of amoxicillin-clavulanate for 7 days, fluconazole 150 mg on days 1, 4, and 7, and intensive vaginal and oral Lactobacillus probiotic support appropriate and safe?
What are the risk factors for venous thromboembolism (VTE)?
What are the differences between myoglobinuria and hematuria, including urine color?
Is there any clinically significant drug‑drug interaction between pantoprazole and lurasidone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.